DK3848028T5 - Fremgangsmåder til behandling af øjenlidelser - Google Patents

Fremgangsmåder til behandling af øjenlidelser Download PDF

Info

Publication number
DK3848028T5
DK3848028T5 DK20212556.3T DK20212556T DK3848028T5 DK 3848028 T5 DK3848028 T5 DK 3848028T5 DK 20212556 T DK20212556 T DK 20212556T DK 3848028 T5 DK3848028 T5 DK 3848028T5
Authority
DK
Denmark
Prior art keywords
methods
eye disorders
treating eye
treating
disorders
Prior art date
Application number
DK20212556.3T
Other languages
Danish (da)
English (en)
Other versions
DK3848028T3 (da
Inventor
Douglas Michael Ackermann Jr
James Loudin
Kenneth J Mandell
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3848028(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Application granted granted Critical
Publication of DK3848028T3 publication Critical patent/DK3848028T3/da
Publication of DK3848028T5 publication Critical patent/DK3848028T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
DK20212556.3T 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser DK3848028T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066280P 2014-10-20 2014-10-20
US201562100844P 2015-01-07 2015-01-07
EP15852340.7A EP3209295B2 (en) 2014-10-20 2015-10-19 Methods of treating ocular conditions

Publications (2)

Publication Number Publication Date
DK3848028T3 DK3848028T3 (da) 2024-08-26
DK3848028T5 true DK3848028T5 (da) 2025-01-20

Family

ID=55748136

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15852340.7T DK3209295T4 (da) 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser
DK20212556.3T DK3848028T5 (da) 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15852340.7T DK3209295T4 (da) 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser

Country Status (21)

Country Link
US (14) US9597284B2 (enExample)
EP (3) EP4413974A3 (enExample)
JP (3) JP6873906B2 (enExample)
KR (2) KR102601505B1 (enExample)
CN (3) CN111956650B (enExample)
AU (2) AU2015336216B2 (enExample)
BR (2) BR122022025737B1 (enExample)
CA (1) CA2965129C (enExample)
DK (2) DK3209295T4 (enExample)
EA (1) EA035335B1 (enExample)
ES (2) ES2848977T5 (enExample)
FI (1) FI3848028T3 (enExample)
IL (3) IL293188B2 (enExample)
MX (2) MX392383B (enExample)
MY (1) MY186870A (enExample)
PH (1) PH12017500602A1 (enExample)
PL (1) PL3848028T3 (enExample)
PT (2) PT3848028T (enExample)
SG (2) SG11201703135XA (enExample)
WO (1) WO2016064759A1 (enExample)
ZA (1) ZA201703467B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3848028T (pt) 2014-10-20 2024-09-20 Oyster Point Pharma Inc Métodos de tratamento de estados oculares
PT3439661T (pt) * 2016-04-07 2021-09-30 Oyster Point Pharma Inc Métodos de tratamento de condições oculares
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2021222230A1 (en) 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
DE102023208057A1 (de) * 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
EP1461040B1 (en) 2001-11-29 2006-03-15 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2583101A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
CA2586074C (en) * 2004-11-09 2013-07-23 Novagali Pharma Sa Ophthalmic oil-in-water type emulsion with stable positive zeta potential
US20090023819A1 (en) * 2005-03-22 2009-01-22 Anders Axelsson Use of an Artificial Sweetener to Enhance Absorption of Nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
WO2007025286A2 (en) 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US8182841B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
TWI404532B (zh) 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
ES2368286T3 (es) * 2007-02-02 2011-11-16 Pfizer Products Inc. Compuestos tricíclicos y su uso como moduladores de los receptores de glucocorticoides.
ES2521494T3 (es) * 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20090215787A1 (en) 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
AU2009221860A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes
CN102143963A (zh) 2008-09-05 2011-08-03 塔加西普特公司 二氮杂双环辛烷的酰胺及其应用
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
CA2742366C (en) 2008-12-01 2020-09-22 Targacept, Inc. Synthesis and salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) * 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
WO2012174338A2 (en) * 2011-06-15 2012-12-20 Glaxosmithkline Llc Method of selecting therapeutic indications
KR20140027939A (ko) * 2011-06-30 2014-03-07 도레이 카부시키가이샤 지양제
CA3083244C (en) * 2011-10-20 2023-01-03 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
CN104094114A (zh) * 2011-11-30 2014-10-08 黛尔格诺斯蒂尔有限公司 干眼诊断
ES2426517B1 (es) * 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
AU2014239842B2 (en) 2013-03-15 2018-07-19 Glia, Llc Cranial delivery of pharmaceuticals
WO2014172693A2 (en) 2013-04-19 2014-10-23 Oculeve, Inc. Nasal stimulation devices and methods
PT3848028T (pt) 2014-10-20 2024-09-20 Oyster Point Pharma Inc Métodos de tratamento de estados oculares
PT3439661T (pt) 2016-04-07 2021-09-30 Oyster Point Pharma Inc Métodos de tratamento de condições oculares
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions

Also Published As

Publication number Publication date
US20160106744A1 (en) 2016-04-21
BR122022025737B1 (pt) 2023-12-26
PT3209295T (pt) 2021-02-05
EP4413974A3 (en) 2024-10-09
KR20230042144A (ko) 2023-03-27
US10456396B2 (en) 2019-10-29
DK3848028T3 (da) 2024-08-26
EP3209295B1 (en) 2020-12-09
US20160106745A1 (en) 2016-04-21
CA2965129C (en) 2024-03-12
BR112017008097A2 (pt) 2018-02-20
US20230226053A1 (en) 2023-07-20
US20230226054A1 (en) 2023-07-20
US11903942B2 (en) 2024-02-20
ES2848977T5 (es) 2024-06-06
MX392383B (es) 2025-03-24
JP2017531044A (ja) 2017-10-19
DK3209295T3 (da) 2021-03-01
KR102511955B1 (ko) 2023-03-22
IL293188B1 (en) 2025-02-01
SG10202011669PA (en) 2020-12-30
JP2023024574A (ja) 2023-02-16
CN111956650A (zh) 2020-11-20
PT3848028T (pt) 2024-09-20
JP7257371B2 (ja) 2023-04-13
JP6873906B2 (ja) 2021-05-19
US9532944B2 (en) 2017-01-03
US20160106746A1 (en) 2016-04-21
US20220233528A1 (en) 2022-07-28
CA2965129A1 (en) 2016-04-28
AU2020213351B2 (en) 2023-04-06
JP7502404B2 (ja) 2024-06-18
CN111956803B (zh) 2025-10-31
US20230226052A1 (en) 2023-07-20
US20170239244A1 (en) 2017-08-24
EA201790893A1 (ru) 2018-01-31
EP3848028B9 (en) 2024-10-16
US20250255865A1 (en) 2025-08-14
JP2021038250A (ja) 2021-03-11
CN111956650B (zh) 2024-06-04
CN107106542A (zh) 2017-08-29
AU2020213351A1 (en) 2020-08-27
CN107106542B (zh) 2020-05-08
US20200246336A1 (en) 2020-08-06
PL3848028T3 (pl) 2024-11-18
BR112017008097B1 (pt) 2023-03-28
MY186870A (en) 2021-08-26
US11903943B2 (en) 2024-02-20
AU2015336216B2 (en) 2020-05-21
US11903941B2 (en) 2024-02-20
EP3848028A1 (en) 2021-07-14
ES2986830T3 (es) 2024-11-12
US20250275963A1 (en) 2025-09-04
EP3209295B2 (en) 2023-12-06
EP4413974A2 (en) 2024-08-14
US11911380B2 (en) 2024-02-27
DK3209295T4 (da) 2024-02-26
US9504645B2 (en) 2016-11-29
US9504644B2 (en) 2016-11-29
ES2848977T3 (es) 2021-08-13
US20250235449A1 (en) 2025-07-24
EP3209295A1 (en) 2017-08-30
PH12017500602A1 (en) 2017-09-04
EA035335B1 (ru) 2020-05-28
MX2022005888A (es) 2022-06-14
WO2016064759A1 (en) 2016-04-28
IL293188A (en) 2022-07-01
KR20170086040A (ko) 2017-07-25
KR102601505B1 (ko) 2023-11-14
IL251769A0 (en) 2017-06-29
EP3209295A4 (en) 2018-05-23
US11224598B2 (en) 2022-01-18
US9597284B2 (en) 2017-03-21
MX2017005064A (es) 2018-02-23
SG11201703135XA (en) 2017-05-30
IL318427A (en) 2025-03-01
IL293188B2 (en) 2025-06-01
EP3848028B1 (en) 2024-05-29
US20240173318A1 (en) 2024-05-30
AU2015336216A1 (en) 2017-06-08
FI3848028T3 (fi) 2024-08-21
CN111956803A (zh) 2020-11-20
IL251769B (en) 2022-06-01
US20160106665A1 (en) 2016-04-21
ZA201703467B (en) 2023-12-20

Similar Documents

Publication Publication Date Title
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
IL257252A (en) Methods of treating fgf21-associated disorders
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
IL249981A0 (en) Method
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
DK3110988T3 (da) Metoder til behandling af lithiumholdige materialer
DK3851537T3 (da) Behandling af hyperbilirubinæmi
BR112016030368A2 (pt) composição oftálmica
DK3718507T3 (da) Anordninger til behandling af nedre ekstremitetsvaskulatur
DK3560954T3 (da) Modificeret j-kæde
IL256912B1 (en) Methods of treating developmental disorders with gaboxadol
EP3209331C0 (en) OPHTHALMIC SOLUTION
DK3231444T3 (da) Ny behandling
DK3134084T3 (da) Fremgangsmåde til behandling af lungeadenokarcinom
DK3122308T3 (da) Indretning til behandling af smerte
DK3191182T3 (da) Apparat til tilvejebringelse af hypertermiterapi
DK3393579T3 (da) Øjenbehandlingssystem
DK3393468T3 (da) Fremgangsmåder til behandling af en immundefektsygdom
DK3848028T5 (da) Fremgangsmåder til behandling af øjenlidelser
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
DK3164716T3 (da) Fremgangsmåde til diagnosticering af neurodegenerative sygdomme
DK3122349T3 (da) Sammensætninger til behandling af autodigestion
FI20145633A7 (fi) Menetelmä biolietteen käsittelemiseksi
IL252086A0 (en) Novel methods